Genomic drugs to have joint venture support facility in Japan
A partnership has been established between Iberica, Kurume University and a proteomics subsidiary of general trading house Itochu to develop a facility to offer comprehensive support for therapeutic trials of genomic drugs.
A partnership has been established between Iberica, Kurume University and a proteomics subsidiary of general trading house Itochu to develop a facility to offer comprehensive support for therapeutic trials of genomic drugs.
Called the Kurume Translational Research Center, the new facility will shortly begin operations at the university's teaching hospital.
Fukuoka-based Iberica, which helps drugmakers conduct therapeutic trials at teaching hospitals and provides the data analysis, has invested ¥500m (€3.65m) in the venture. The joint facility will be able to support all stages of therapeutic trials, from handling inpatients and carrying out clinical testing to proteomic analysis of samples and processing data using bioinformatics.